Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcus Biosciences Inc (RCUS)
NYSE:RCUS
RCUS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.65 - $20.31
Previous CloseN/A
Volume107.84K
Average Volume (3M)917.90K
Market Cap
$1.00B
Enterprise Value$366.51M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Feb 25, 2025EPS Estimate
-1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.15
Shares Outstanding105,147,970
10 Day Avg. Volume1,412,225
30 Day Avg. Volume917,903
Standard Deviation0.23
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.86
Price to Cash Flow (P/CF)9.80
P/FCF Ratio9.80
Enterprise Value/Market Cap0.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.64
Enterprise Value/Ebitda-1.44
Forecast
1Y Price Target
$28.14Price Target Upside162.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentArcus Biosciences gains full rights to the drug Cas after GILD's exclusive option rights expired, allowing them to develop it independently.
Financial PositionArcus Biosciences reported having approximately $992 million in cash and equivalents, providing a financial runway into mid-2027.
Bears Say
Stock OfferingArcus' $150M raise is pressuring shares and contributing to a recent pullback in stock value.
---
Ownership Overview
6.46% Insiders
15.23% Mutual Funds
51.34% Other Institutional Investors
11.54% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RCUS FAQ
What was Arcus Biosciences Inc’s price range in the past 12 months?
Arcus Biosciences Inc lowest stock price was $10.65 and its highest was $20.31 in the past 12 months.
What is Arcus Biosciences Inc’s market cap?
Arcus Biosciences Inc’s market cap is $1.00B.
When is Arcus Biosciences Inc’s upcoming earnings report date?
Arcus Biosciences Inc’s upcoming earnings report date is Feb 25, 2025 which is in 3 days.
How were Arcus Biosciences Inc’s earnings last quarter?
Arcus Biosciences Inc released its earnings results on Nov 06, 2024. The company reported -$1 earnings per share for the quarter, beating the consensus estimate of -$1.056 by $0.056.
Is Arcus Biosciences Inc overvalued?
According to Wall Street analysts Arcus Biosciences Inc’s price is currently Undervalued.
Does Arcus Biosciences Inc pay dividends?
Arcus Biosciences Inc does not currently pay dividends.
What is Arcus Biosciences Inc’s EPS estimate?
Arcus Biosciences Inc’s EPS estimate is -1.25.
How many shares outstanding does Arcus Biosciences Inc have?
Arcus Biosciences Inc has 105,147,970 shares outstanding.
What happened to Arcus Biosciences Inc’s price movement after its last earnings report?
Arcus Biosciences Inc reported an EPS of -$1 in its last earnings report, beating expectations of -$1.056. Following the earnings report the stock price went up 4.641%.
Which hedge fund is a major shareholder of Arcus Biosciences Inc?
Currently, no hedge funds are holding shares in RCUS
---
Arcus Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.14 (162.01% Upside)
$28.14 (162.01% Upside)
Blogger Sentiment
Bullish
RCUS Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $15.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.5%
Last 30 Days ▲ 12.3%
Last 30 Days ▲ 12.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.30%
12-Months-Change
Fundamentals
Return on Equity
-49.77%
Trailing 12-Months
Asset Growth
5.12%
Trailing 12-Months
Company Description
Arcus Biosciences Inc
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
---
RCUS Company Deck
---
RCUS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong data for key drug candidates, significant progress in clinical trials, and a stable financial position, although strategic uncertainties with collaborations and competitive challenges in the RCC market were noted.Read More>---
RCUS Stock 12 Month Forecast
Average Price Target
$28.14
▲(162.01% Upside)
Technical Analysis
Best Analysts Covering RCUS
1 Year
1 Year Success Rate
3/10 ratings generated profit
1 Year Average Return
-14.57%
reiterated a buy rating 4 days ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of -14.57% per trade.
---